Pfizer's chief scientific officer joins Agilent Technologies board.

• Author: Wenger, Barbara
• Position: DIRECTORS & BOARD'S DIRECTOR ROSTER

Mikael Dolsten, chief scientific officer and president of worldwide research, development and medical at Pfizer Inc., has joined the board of Agilent Technologies. Dolsten has been involved in advancing more than 30 drugs and vaccines to approval. Most recently, he co-led Pfizer's collaboration with BioNTech to develop its Comirnaty COVID-19 mRNA vaccine.

"Mikael's outstanding scientific, medical and research background makes him a valuable addition to the Agilent board," said Mike McMullen, Agilent president and CEO. "His leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines will be a key asset for Agilent moving forward." Dolsten has served in a variety of roles for Pfizer since 2009, including chief scientific officer; president of R&D; and senior vice president and division president, biotherapeutics research and development. In his current role, he leads a team of more than 8,000 scientists and oversees all global research operations across six therapeutic areas for Pfizer. Prior to 2009, he was president of Wyeth Research and executive vice president and head of worldwide research for Boethringer Ingelheim.

He has served as an advisorto the Obama administration for regulatory sciences, to then-Vice President Joe Biden in the Cancer Moonshot initiative and to the U. K. government for the 2021G7 Summit.

Agilent Technologies, established in 1999 as a spin-off from Hewlett Packard, is an analytical instrumentation development and manufacturing company that serves worldwide markets. Its global headquarters is in Santa Clara, Calif.--Barbara Wenger

...